Immunotherapy for Anal Cancer — When It Is Used, and Who Is Eligible

Most people diagnosed with anal cancer are not candidates for immunotherapy. Anal cancer is usually found while it is still confined to the anal canal or the nearby lymph nodes. The established treatment at that point is chemoradiotherapy — radiation given together with chemotherapy — and immunotherapy has no routine role there outside a clinical trial.

Chemoradiotherapy is the reason this matters. It is given with the intention of clearing the tumour without an operation, so that the anal sphincter is preserved and a permanent colostomy is avoided. Adding or substituting immunotherapy at that stage is being studied, and is not standard practice as of August 2026.

Immunotherapy enters the discussion in a narrower group. That group is disease that has spread beyond the reach of radiation, and disease that has come back after chemoradiotherapy and cannot be removed by surgery. Both are described in guidance as locally recurrent or metastatic squamous cell carcinoma of the anal canal.

Medical history then decides whether it is safe. Active autoimmune disease, an organ transplant on immunosuppressive drugs, or ongoing high-dose steroids can make checkpoint inhibitor treatment unsuitable or higher-risk. These drugs work by loosening a brake on the immune system rather than by attacking the tumour, so an immune system that is already over-active is a genuine obstacle rather than a form to sign.

Living with HIV is not, by itself, a barrier. Anal cancer is far more common in people living with HIV, and checkpoint inhibitors have been used in that group. It changes the monitoring, not the door.

Nothing on this page decides eligibility. That rests on the biopsy report, the stage, what treatment has already been given and overall fitness, read together by a medical oncologist.

In advanced disease only, and in two positions. The first is alongside chemotherapy as the initial treatment for anal cancer that has spread or has returned and cannot be operated on. The second is on its own, after chemotherapy has stopped controlling the disease. Neither position applies to anal cancer that is still confined and treatable with chemoradiotherapy.

The first-line position is the newer of the two. A randomised phase III trial in first-line advanced anal squamous cell carcinoma, reported at ESMO in 2024 and published in The Lancet in 2025, compared standard platinum-and-taxane chemotherapy with the same chemotherapy plus an anti-PD-1 checkpoint inhibitor. Adding the checkpoint inhibitor improved outcomes over chemotherapy alone. The United States Food and Drug Administration approved that combination for first-line use in May 2025.

The second position is older and more familiar. Checkpoint inhibitors have been listed in NCCN guidance for several years as an option for anal cancer that has progressed after chemotherapy, based on single-arm studies rather than randomised comparisons. Used this way, they help a minority of patients, and the honest framing is that most people who receive one in this setting do not respond.

A third, uncommon route exists. If tumour testing shows high microsatellite instability or mismatch-repair deficiency, checkpoint inhibitor treatment can be considered on that basis regardless of where the cancer started. That finding is unusual in anal squamous cell carcinoma, which is explained further down this page.

Availability in India is a separate question from approval abroad. A regulatory approval in the United States or Europe does not mean the same agent is approved by the Central Drugs Standard Control Organisation and marketed in India. As of August 2026 the Indian approval and supply position for the specific agent used in that first-line trial is not something this page can confirm, and it should be checked with the treating oncologist rather than assumed in either direction.

Read down the first column until you find the situation described on your report. Most people stop at the first or second row.

Pathway summarised from NCCN anal carcinoma guidance and published phase III data current as of August 2026. No survival figure is quoted anywhere on this page, because a number taken out of its trial population tells an individual patient almost nothing.

A real but partial benefit, in advanced disease, for a proportion of patients. The first-line phase III trial showed that adding an anti-PD-1 checkpoint inhibitor to chemotherapy did better than chemotherapy alone. That is the strongest evidence anal cancer has ever had for a systemic treatment, and it is the reason this page exists.

What it does not show is a treatment that works for everyone. Tumours shrink in some patients and not in others. Used on its own after chemotherapy has failed, response is reported in a minority. When a response does happen it can last unusually long, because an immune response, once established, can persist after the drug is stopped. That combination of a modest chance and a potentially durable result is what the whole conversation turns on.

No page should convert that into a percentage for you. The trial population was selected, it was largely not Indian, and the numbers were generated in patients who had specific prior treatment and a specific level of fitness. The useful question for your own consultation is not what the response rate was, but what the plan is if the first assessment scan is disappointing, and whether a trial is worth exploring.

Side effects deserve equal billing. Checkpoint inhibitors cause immune-related reactions rather than the predictable pattern of chemotherapy: inflammation of the bowel, the lungs, the liver, the thyroid or, rarely, the heart. In anal cancer this is particularly worth flagging, because bowel symptoms after pelvic chemoradiotherapy are already common, and telling radiation-related bowel change apart from immune-related colitis needs the treating team, not a search engine.

At CION, immunotherapy is administered as day care at our centres. Response-assessment CT and PET-CT imaging is coordinated at partner imaging centres rather than performed in-house.

No. A microsatellite-stable result does not rule you out. MSI-high and mismatch-repair-deficient tumours qualify for checkpoint inhibitor treatment on a tumour-agnostic basis, whatever the organ of origin. But in anal cancer, eligibility for immunotherapy rests mainly on the site-specific indication for advanced disease, not on the MSI result.

This distinction is worth getting right because it is routinely inverted. Anal squamous cell carcinoma is overwhelmingly HPV-driven, and HPV-driven tumours are usually microsatellite stable. An MSI-high finding here is uncommon. If eligibility genuinely depended on it, almost nobody with anal cancer would ever be offered immunotherapy — and that is not what guidance says.

Interpretation summarised from NCCN guidance current as of August 2026. Ask for the actual report wording rather than a verbal summary — MSI, MMR and PD-L1 are three different tests and are frequently confused with each other.

• Hepatitis B and hepatitis C screening. Hepatitis B surface antigen, core antibody and hepatitis C antibody are checked as protocol before immunotherapy. India has a substantial population of people carrying hepatitis B without knowing it, and if an immune-related side effect later needs steroids, an unrecognised infection can reactivate. Knowing the status in advance changes the monitoring and, where indicated, adds antiviral cover.
• HIV testing, also as protocol. Anal cancer is strongly associated with HIV, so this is asked of everyone rather than of selected patients. A positive result does not close off immunotherapy. It changes who co-manages the treatment and how closely counts are followed.
• Thyroid and adrenal baseline. Thyroid function and a morning cortisol are checked before the first cycle, because the thyroid and the pituitary-adrenal axis are among the more common sites of immune-related inflammation and a baseline makes a later change interpretable.
• Liver, kidney and blood counts. Baseline organ function decides whether treatment can start safely and gives every later result something to be compared against.
• A dated baseline scan. Response is judged by comparing a later scan with this one. Without a recent baseline there is nothing to measure against, and the first assessment becomes guesswork.

• For a disease where immunotherapy displaced chemotherapy as the first treatment rather than being added to it, see Immunotherapy for Mesothelioma — the clearest example of a rare cancer where the standard genuinely moved.
• Anal cancer is virus-driven, and so is another rare cancer that responds unusually often — Immunotherapy for Merkel Cell Carcinoma explains why a viral cause makes a tumour easier for the immune system to see.
• If you want the longest-standing example of checkpoint inhibitors working in a young, otherwise fit population, Immunotherapy for Hodgkin Lymphoma covers a very different disease treated on the same principle.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Unsure how any of this applies to a specific report? Book a free consultation and a medical oncologist will read it with you.